The global sterile injectable drugs market has been envisioned by Transparency Market Research (TMR) to hold a significantly concentrated nature for its vendor landscape. In a new report by TMR, some of the important players of the market have been profiled by the analysts, including AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Sanofi, and Baxter International Inc. The authors of the report have elaborately profiled the players in order to provide a sound understanding of how the competitive landscape could shape in the near future. Readers have been anticipated to become familiar with future competitive scenarios and prepare beforehand for any prospective changes.
The global sterile injectable drugs market has been predicted in the TMR report to earn an estimated US$901.3 bn by the end of 2025 at a CAGR of 11.1% for the forecast tenure 2017-2025. In 2017, the market earned a US$387.1 bn. In terms of a segmentation by type, the large molecule market had earned a colossal share of 54.6% in 2016. By region, North America had secured a commanding position in the global market with a 43.0% share in 2016.
Need for Immediate Response in Chronic Disease Cases Raises Growth
The world sterile injectable drugs market has been expected to gain impetus due to the increasing preference for large molecule drugs over traditional ones. Cases of chronic disease which often require an immediate response include treatments using large molecule drugs, particularly in heart congestion and cancer cases. Nevertheless, small molecule drugs have also been projected to support the growth of the market, if not in like manner as large molecule drugs. These days, small molecule drugs have been adopted in oncology. Furthermore, their less cost and easy manufacturing could raise their preference in the coming years.
Developed countries such as the U.K., Germany, and the U.S. witnessing an aggressive development of healthcare accessibilities and a rising count of diseases have been forecast to help monoclonal antibodies to register a faster growth in the foreseeable future.
Expensive Operations and Tall Initial Investments Suppress Demand
The international sterile injectable drugs market has been envisaged to be hindered by a loss in demand owing to high operational expenses and initial investments. Moreover, the complex manufacturing process of sterile injectable drugs could dampen market growth during the course of the forecast tenure. As a result, only a handful of new players have been able to enter the market. There could be a shortage in the supply of sterile injectable drugs due to a high degree of care and quality required to be ensured at different stages, viz. distribution, storage, packaging, and manufacturing. This could be due to the highly infectious and toxic nature of the drugs and rise of stringent government regulations.
Howbeit, rising healthcare awareness pertaining to the management and treatment of chronic diseases, extensive research and development, and technological advancement have been prognosticated to be some of the crucial factors helping market growth to make a strong comeback. The international sterile injectable drugs market could be positively impacted by the advent of biotechnological products derived from human or other biologic sources.
The information presented in this review is based on a TMR report, titled “Sterile Injectable Drugs Market (Type - Small Molecule and Large Molecule; Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, and Peptide Antibiotics; Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, and Infectious Diseases; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Ecommerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.”
The global sterile injectable drugs market has been segmented as presented below:
Global Sterile Injectable Drugs Market by Type
- Small Molecule
- Large Molecule
Global Sterile Injectable Drugs Market by Drug Class
- Monoclonal Antibodies (Mabs)
- Peptide Hormones
- Blood Factors
- Peptide Antibiotics
Global Sterile Injectable Drugs Market by Indication
- Cardiology and Metabolic Disorders
- Infectious Diseases
Global Sterile Injectable Drugs Market by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Global Sterile Injectable Drugs Market by Geography
- North America
- Rest of the Europe
- Asia Pacific (APAC)
- Australia and New Zealand
- Rest of APAC
- Latin America (LATAM)
- Rest of LATAM
- Middle East and Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact